Full Text View
Tabular View
Study Results
Related Studies
To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)
This study has been completed.
Study NCT00271817   Information provided by Merck

First Received on January 3, 2006.   Last Updated on April 3, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hypercholesterolemia
Additional conditions recognized in this trial
Hyperlipidemias
More general conditions related to this trial
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Interventions listed in this trial
Comparator: niacin (ER) tablet
Comparator: Placebo to Niacin (ER)
Additional drug interventions recognized in this trial
Ezetimibe
Niacin
Niacinamide
Nicotinic Acids
Simvastatin
More general drug interventions related to this trial
Anticholesteremic Agents
Antimetabolites
Cardiovascular Agents
Enzyme Inhibitors
Growth Substances
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypolipidemic Agents
Lipid Regulating Agents
Micronutrients
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Vasodilator Agents
Vitamin B Complex
Vitamins
Sponsors listed in this trial
Merck


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services